logo-loader
HealthPharma & Biotech
MaxCyte

MaxCyte extends relationship with Gilead Sciences-owned cancer drug developer Kite

Kite will use MaxCyte's Flow Electroporation cell engineering platform to help it develop “multiple” CAR-T drug candidates for up to ten targets

cell engineering
This latest agreement builds on a deal announced last November

Life sciences group MaxCyte Inc (LON:MXCT) has extended its relationship with Kite – the multi-billion-dollar cancer drug developer owned by US giant Gilead Sciences.

Under the terms of this latest agreement, Kite will use MaxCyte’s Flow Electroporation technology to help it develop “multiple” CAR-T drug candidates for up to ten targets.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

“We're excited to take our relationship with Kite further into product development, providing the company with the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics,” said MaxCyte president and chief executive Doug Doerfler.

In CAR-T, patient immune cells are extracted, genetically modified with a receptor to target certain cancer cells, then reinfused back into the patient.

This is where MaxCyte’s technology comes in: it allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance.

In return for granting Kite the non-exclusive rights to use its cell engineering platform, Maryland, US-based MaxCyte will receive development and approval milestones and sales-based payments, as well as other licensing fees.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018.

Quick facts: MaxCyte

Price: £1.22

Market: AIM
Market Cap: £69.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte named herein, including the promotion by the Company of MaxCyte in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read